Oncotarget

Research Papers:

Prognostic role of cyclin B1 in solid tumors: a meta-analysis

Chenyang Ye, Ji Wang, Pin Wu, Xiaofen Li and Ying Chai _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:2224-2232. https://doi.org/10.18632/oncotarget.13653

Metrics: PDF 1932 views  |   HTML 2356 views  |   ?  


Abstract

Chenyang Ye1,*, Ji Wang3,*, Pin Wu2, Xiaofen Li1, Ying Chai2

1Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, National Ministry of Education, Provincial Key Laboratory of Molecular Biology in Medical Sciences), Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, China

2Department of Thoracic Surgery, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, China

3Department of Surgical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou 310016, China

*These authors contributed equally to this work

Correspondence to:

Ying Chai, email: [email protected]

Keywords: cyclin B1, solid tumors, prognosis, overall survival, meta-analysis

Received: October 07, 2016     Accepted: November 16, 2016     Published: November 26, 2016

ABSTRACT

Cyclin B1 is a key mitotic cyclin in the G2-M phase transition of the cell cycle and is overexpressed in various malignant tumors. Numerous studies have reported contradictory evidences of the correlation between cyclin B1 expression and prognosis in human solid tumors. To address this discrepancy, we conducted a meta-analysis with 17 published studies searched from PubMed and Medline. Cyclin B1 overexpression was significantly associated with poor 3-year overall survival (OS) (OR = 2.05, 95% CI = 1.20 to 3.50, P = 0.009) and 5-year OS (OR = 2.11, 95% CI = 1.33 to 3.36, P = 0.002) of solid tumors. Subgroup analysis revealed that elevated cyclin B1 expression was associated with worse prognosis of lung cancer and esophageal cancer but better prognosis of colorectal cancer. In summary, overexpression of cyclin B1 is correlated with poor survival in most solid tumors, which suggests that the expression status of cyclin B1 is a significant prognostic parameter in solid tumors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13653